As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity Purchase Ag...
This letter agreement follows our conversation of August 19, 2026, regarding your employment with TransCode Therapeutics, Inc. (the “Company”) and confirms the termination of your employment with the Company effective September 9, 2026 (...